Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ewing sarcoma (EWS) is a tumour most commonly arising in bone, although on occasion in soft tissue, with a poor prognosis in patients with refractory or relapsed disease, despite multimodal therapy. Immunotherapeutic strategies based on tumour‐reactive T and/or natural killer cells may improve the treatment of advanced‐stage EWS. Since cellular immune recognition critically depends on human leukocyte antigen (HLA) expression, knowledge about HLA expression in EWS is crucial in the design of cellular immunotherapeutic strategies. Constitutive and IFNγ‐induced HLA class I expression was analysed in EWS cell lines ( n = 6) by flow cytometry, using antibodies against both monomorphic and allele‐specific antigens. Expression of antigen processing pathway components and beta‐2 microglobulin (β2m) was assessed by western blot. Expression of class II transactivator (CIITA), and its contribution to HLA class II expression, was evaluated by qRT‐PCR, transduction assays, and flow cytometry. β2m/HLA class I and class II expression was validated in EWS tumours ( n = 67) by immunofluorescence. Complete or partial absence of HLA class I expression was observed in 79% of EWS tumours. Lung metastases consistently lacked HLA class I and sequential tumours demonstrated a tendency towards decreased expression upon disease progression. Together with absent or low constitutive expression levels of specific HLA class I loci and alleles, and differential induction of identical alleles by IFNγ in different cell lines, these results may reflect the existence of an immune escape mechanism. Inducible expression of TAP‐1/‐2, tapasin, LMP‐2/‐7, and the β2m/HLA class I complex by IFNγ suggests that regulatory mechanisms are mainly responsible for heterogeneity in constitutive class I expression. EWSs lack IFNγ‐inducible HLA class II, due to lack of functional CIITA. The majority of EWS tumours, particularly if advanced‐stage, exhibit complete or partial absence of both classes of HLA. This knowledge will be instrumental in the design of cellular immunotherapeutic strategies for advanced‐stage EWS. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STRUCTURE, FUNCTION, AND DIVERSITY OF CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES
Bjorkman, P. J., & Parham, P. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.001345 · Cited by 700
Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Self-citationA proposed role for neutrophil extracellular traps in cancer immunoediting
Berger-Achituv, S., Brinkmann, V., Abed, U. A., Kühn, L. I., Ben-Ezra, J., Elhasid, R., & Zychlinsky, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00048 · Cited by 288
Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1250050 · Cited by 104
“downregulate surface MHC class I and thereby fail to bind to inhibitory NK cell receptors, further shifting the balance toward NK cell activation.(5,6) But within a multicellular tumor architecture, EwS cells can develop NK cell resistance,(6) and reports of patients”
BackgroundHolmes, T. D., El-Sherbiny, Y. M., Davison, A., Clough, S. L., Blair, G. E., & Cook, G. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000951 · Cited by 52
Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application
Wei, R., Dean, D. C., Thanindratarn, P., Hornicek, F. J., Guo, W., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.024 · Cited by 48
Metadata
- Authors
- Berghuis, D., de Hooge, A. S., Santos, S. J., Horst, D., Wiertz, E. J., van Eggermond, M. C., van den Elsen, P. J., Taminiau, A. H., Ottaviano, L., Schaefer, K., Dirksen, U., Hooijberg, E., Mulder, A., Melief, C. J., Egeler, R. M., Schilham, M. W., Jordanova, E. S., Hogendoorn, P. C., & Lankester, A. C.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2009-03-09
- Volume
- 218
- Issue
- 2
- Pages
- 222-231
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2125354405
- Cited by
- 93
- References
- 2
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition. https://app.cochat.ai/papers/10.1002/path.2537
- The paper
- Berghuis, D., de Hooge, A. S., Santos, S. J., Horst, D., Wiertz, E. J., van Eggermond, M. C., van den Elsen, P. J., Taminiau, A. H., Ottaviano, L., Schaefer, K., Dirksen, U., Hooijberg, E., Mulder, A., Melief, C. J., Egeler, R. M., Schilham, M. W., Jordanova, E. S., Hogendoorn, P. C., & Lankester, A. C. (2009). Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition. The Journal of Pathology. https://doi.org/10.1002/path.2537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.